Overview

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis
Phase:
Phase 3
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd